Shenzhen Kaifa Technology
920029
Highbroad Advanced Material
301321
WuHan Hvsen Biotechnology
300871
4
Shanghai Yongli Belting
300230
5
Fujian Superpipe
300198
US Stock MarketDetailed Quotes
APVO Aptevo Therapeutics
- 1.250
- -0.290-18.83%
Close Mar 27 16:00 ET
- 1.220
- -0.030-2.40%
Post 20:01 ET
1.82MMarket Cap-0.01P/E (TTM)
1.540High1.230Low182.74KVolume1.530Open1.540Pre Close239.96KTurnover12.53%Turnover RatioLossP/E (Static)1.46MShares180.19052wk High0.38P/B1.82MFloat Cap1.23052wk Low--Dividend TTM1.46MShs Float144729.200Historical High--Div YieldTTM20.12%Amplitude1.230Historical Low1.313Avg Price1Lot Size
Aptevo Therapeutics Stock Forum
Sign in to post a comment
$Aptevo Therapeutics (APVO.US)$ why it keeps sinking? any news? @Trytosaveabit do you have any insight on this pls???
2
2
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
31
14
2
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
$Aptevo Therapeutics (APVO.US)$
Breakthrough: New AML Drug Shows 90% Success Rate, Outperforming Standard Therapy by 24%
Breakthrough: New AML Drug Shows 90% Success Rate, Outperforming Standard Therapy by 24%
1
$Aptevo Therapeutics (APVO.US)$ RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Accesswire· 2 mins ago
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care
Triplet Combination with mipletamig continues to outperform doublet combination benchmark
No Cytokine Release Syndrome (CRS) has been observed in the RAINIER trial to date
Cohort 2 enrollment nears co...
Accesswire· 2 mins ago
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care
Triplet Combination with mipletamig continues to outperform doublet combination benchmark
No Cytokine Release Syndrome (CRS) has been observed in the RAINIER trial to date
Cohort 2 enrollment nears co...
1
$Aptevo Therapeutics (APVO.US)$
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Thursday, 20th March at 8:35 am
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care
Triplet Combination with mipletamig continues to outperform doublet combination benchmark
No Cytokine Release Syndrome (CRS) has been observed in the RAINIER trial to date
Cohort 2 enrollme...
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Thursday, 20th March at 8:35 am
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care
Triplet Combination with mipletamig continues to outperform doublet combination benchmark
No Cytokine Release Syndrome (CRS) has been observed in the RAINIER trial to date
Cohort 2 enrollme...
3
1
$Aptevo Therapeutics (APVO.US)$
Breakthrough Cancer Drug APVO603 Targets Two Immune Pathways to Fight Solid Tumors
Breakthrough Cancer Drug APVO603 Targets Two Immune Pathways to Fight Solid Tumors
$Aptevo Therapeutics (APVO.US)$
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
Tuesday, 18th March at 8:05 am
Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action
SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ: APVO), a leader in the development of novel bispecific antibodies for cancer treatment, based on its proprietary ADAPTIR® ...
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
Tuesday, 18th March at 8:05 am
Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action
SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ: APVO), a leader in the development of novel bispecific antibodies for cancer treatment, based on its proprietary ADAPTIR® ...
1
$Aptevo Therapeutics (APVO.US)$ everyday ATL
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
$Aptevo Therapeutics (APVO.US)$
Exclusive: Aptevo's Revolutionary Cancer Treatment Achieves 100% Remission Rate - CEO Interview Alert
Exclusive: Aptevo's Revolutionary Cancer Treatment Achieves 100% Remission Rate - CEO Interview Alert
1
$Aptevo Therapeutics (APVO.US)$
The clinical data presented by Aptevo Therapeutics demonstrates remarkable efficacy signals that warrant careful attention. In the RAINIER trial, mipletamig's 100% remission rate within 30 days in Cohort 1 is particularly noteworthy, as typical remission rates for standard venetoclax/azacitidine therapy in AML range from 65-70%. The achievement of MRD negativity in one patient is espec...
The clinical data presented by Aptevo Therapeutics demonstrates remarkable efficacy signals that warrant careful attention. In the RAINIER trial, mipletamig's 100% remission rate within 30 days in Cohort 1 is particularly noteworthy, as typical remission rates for standard venetoclax/azacitidine therapy in AML range from 65-70%. The achievement of MRD negativity in one patient is espec...
1
No comment yet
Market Insights
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Trytosaveabit : So first its just awful low volume! And i believe some of the drop is because of a filing of a S1-A This morning to approve more shares for employees!
71370988 OP Trytosaveabit : thank you